Terms ending in 2028
Every in-force patent on Biogen Ma Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,609,407 | Sp35 Antibodies and Uses Thereof In force · Medium confidence | Biogen Ma Inc. | In force | Medium confidence | |
| US 8,399,514 | Treatment for Multiple Sclerosis In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 8,784,823 | Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 9,321,840 | Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 8,232,064 | Detection and Quantitation of Cyclodextrins In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,138,461 | Compositions and Methods for Increasing Vascularization In force · High confidence | Sinfonia Biotherapeutics AB | In force | High confidence | |
| US 7,846,438 | Methods of Promoting Neurite Outgrowth with Soluble Taj Polypeptides In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US RE44,681 | Compositions and Methods for Inhibiting Growth of SMAD4-DEFICIENT Cancers In force · Low confidence | Biogen Ma Inc. | In force | Low confidence | |
| US D707,352 | Medicament Delivery Device In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 8,202,698 | Methods of Evaluating Baff In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| 1 more term end in 2028 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11, including 6 expiring within the 18 months from Nov 21, 2026.
8 of these are in force and held by Biogen Ma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.